BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
일요일, 9월 27

Halozyme Therapeutics Inc

HALONASDAQ
Trade with Public
Trade with Public
$113.90
-1.32-1.15%
가까이에: Sep 25, 5:00 PM EST
$114.18
0.280.25%
시간외: Sep 25, 4:02 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Halozyme Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Halozyme Therapeutics (HALO).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

2S.Buy
5Buy
3Hold
Consensus RatingMarket Outperform# Analysts10Avg. Consensus PT$83Upside to Avg. PT-27.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$115
Aug 7, 2026Leerink PartnersDavid RisingerUpgradeMarket Perform→Outperform$83→$110
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $115 price target.
Benzinga Newsdesk

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $92 to $93.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $75 to $95.
Benzinga Newsdesk

Atlassian To Rally More Than 63%? Here Are 10 Top Analyst Forecasts For Friday

Wall Street analysts changed ratings & price targets for top stocks. Check out all changes including upgrades & downgrades on Benzinga analyst ratings page.
Avi Kapoor

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved